These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 15879821)

  • 1. Can a baseline prostate specific antigen level identify men who will have lower urinary tract symptoms later in life?
    Carter HB; Landis P; Wright EJ; Parsons JK; Metter EJ
    J Urol; 2005 Jun; 173(6):2040-3. PubMed ID: 15879821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship among lower urinary tract symptoms, prostate specific antigen and erectile dysfunction in men with benign prostatic hyperplasia: results from the proscar long-term efficacy and safety study.
    Paick SH; Meehan A; Lee M; Penson DF; Wessells H
    J Urol; 2005 Mar; 173(3):903-7. PubMed ID: 15711315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort.
    St Sauver JL; Jacobson DJ; Girman CJ; Lieber MM; McGree ME; Jacobsen SJ
    J Urol; 2006 Mar; 175(3 Pt 1):1018-22; discussion 1022. PubMed ID: 16469608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: a multicentre study.
    Chung BH; Hong SJ; Cho JS; Seong DH
    BJU Int; 2006 Apr; 97(4):742-6. PubMed ID: 16536765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
    Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
    Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms.
    Laniado ME; Ockrim JL; Marronaro A; Tubaro A; Carter SS
    BJU Int; 2004 Dec; 94(9):1283-6. PubMed ID: 15610106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.
    Loeb S; Roehl KA; Antenor JA; Catalona WJ; Suarez BK; Nadler RB
    Urology; 2006 Feb; 67(2):316-20. PubMed ID: 16442597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
    Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
    BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Definition of at-risk patients: baseline variables.
    Roehrborn CG
    BJU Int; 2006 Apr; 97 Suppl 2():7-11; discussion 21-2. PubMed ID: 16507046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum prostate-specific antigen as a predictor of prostate volume in Korean men with lower urinary tract symptoms.
    Shim HB; Lee JK; Jung TY; Ku JH
    Prostate Cancer Prostatic Dis; 2007; 10(2):143-8. PubMed ID: 17199133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate.
    Volkan T; Ihsan TA; Yilmaz O; Emin O; Selcuk S; Koray K; Bedi O
    Eur Urol; 2005 Oct; 48(4):608-13. PubMed ID: 16135396
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum prostate-specific antigen as a predictor of prostate volume in the community: the Krimpen study.
    Bohnen AM; Groeneveld FP; Bosch JL
    Eur Urol; 2007 Jun; 51(6):1645-52; discussion 1652-3. PubMed ID: 17320271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
    Tsukamoto T; Masumori N; Rahman M; Crane MM
    Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of benign prostatic hyperplasia disease.
    Marks LS; Roehrborn CG; Andriole GL
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
    Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
    BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definition of at-risk patients: dynamic variables.
    Emberton M
    BJU Int; 2006 Apr; 97 Suppl 2():12-5; discussion 21-2. PubMed ID: 16507047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
    Emberton M; Lukacs B; Matzkin H; Alcaraz A; Elhilali M; Vallancien G
    J Urol; 2006 Sep; 176(3):1051-6. PubMed ID: 16890690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-reported prevalence of prostate-specific antigen testing in South Australia: a community study.
    Pinnock CB; Weller DP; Marshall VR
    Med J Aust; 1998 Jul; 169(1):25-8. PubMed ID: 9695698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation.
    Lehrer S; Cesaretti J; Stone NN; Stock RG
    BJU Int; 2006 Nov; 98(5):979-81. PubMed ID: 17034599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.